Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoic Acid for Progressive Multiple Sclerosis
NCT03161028Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- Aug 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Lipoic Acid with Placebo (2 arms). Primary endpoint: Timed 25-Foot Walk at 24 months. Started Aug 2018; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03161028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161028.